OMITTED

What the news leaves out.

← Omitted front page

CVS Health to Split Pharmacy and Insurance Businesses

8 sources · updated 2026-11-05
Left 50% Center 0% Right 50%
4 left · 0 center · 4 right

What happened

CVS Health, a U.S. healthcare company valued at about $117 billion that in 2018 acquired insurer Aetna in a roughly $70–78 billion deal, announced it will divide into two publicly traded companies by the first half of 2028. The Wall Street Journal first reported the story on 2026-11-04, the New York Post credited the Journal as the origin, and David Joyner, CVS’s chief executive, was the first on-record source, in The Guardian that same date. One firm, CVS Pharmacy, to be led by Prem Shah, will take the roughly 9,000 retail pharmacies, MinuteClinic in-store clinics, and mail-order prescription operations; the other will keep the CVS Health name under Joyner and hold Aetna, pharmacy-benefit manager Caremark, specialty pharmacy, Oak Street Health primary care, and Signify Health home visits. Existing shareholders are to receive shares in both companies; CVS shares fell about 10 to 13 percent after the Wednesday announcement, which the company said followed a board strategic review.
Sourcing check · Mostly on the record · 8 articles

6 of 8 articles cite a named source for the story. It started with a Wall Street Journal report citing unnamed sources; a named source appeared 15 hours later.

What these terms mean and how they're counted
On the record · names a source 6 of 8
On the record means the article cites a source by name for the story's main claim: a person, or an institution speaking officially, such as a company statement or a named agency's spokesperson. The opposite is an unnamed source. The count is how many of the counted articles cite at least one such source; the names are everyone named across them, each once however the articles spell it. Here: David Joyner, CVS Health, CEO David Joyner, Brian Tanquilut, Michael Cherny and Douglas Hoey
Primary evidence · cites a document or data 2 of 8
Primary evidence means the article cites a record you could check yourself: a court filing or ruling, a dataset or report, a recording or transcript, an official statement or press release, market data. A quote is not a document. The count is how many articles cite one. Here: company announcement, press release, regulatory filing
Credits another outlet 1 of 8
The article says the story comes from another outlet's reporting (“first reported by Reuters”). Those articles relay the story; they are not independent confirmation. Here: Wall Street Journal
Unnamed sources 1 of 8
The main claim is attributed to people who are not identified: “people familiar with the matter”, “officials said”. The count is how many articles do this. Here: e.g. “the Wall Street Journal reported”
How it developed
When the first report landed and whether it named anyone; when the first named source and the first document appeared. Here: First report Nov 4, 00:12 UTC by New York Post, crediting Wall Street Journal, with no named source. First named source 15 hours later, from The Guardian. First document the next day, from Fox Business (company announcement).
Not counted 0
Opinion, analysis and video pieces, and articles too short to assess. Every count above is out of the counted articles. An article republished under a new headline is one article.
This is about who is cited, not whether the story is true. Each source below says what it names. How we count
Omitted — what each side leaves out

Unpacked

Right-leaning coverage presents the breakup as ending CVS's power to steer patients and set what rival pharmacies are paid, but it never reports the plan to keep the pharmacy chain and the PBM commercially linked after they become separate companies. Left-leaning coverage at CNBC has the chief executive saying that synergy would be "preserved in commercial agreements" between the two organizations. Without that fact, the split reads as an unwind of vertical integration rather than a change in corporate form. Left-leaning coverage, especially in the Guardian, opens on lawmakers and regulators pressing giants that dominate the market. Right-leaning coverage at Fox Business opens on independent pharmacies and what the split might mean for patients at the counter. The same announcement is treated first as an antitrust story on one side and a drugstore-competition story on the other. Will the planned contracts between Caremark and CVS pharmacies still count as the integration that Arkansas and Tennessee already tried to ban?
Bottom line

The split is not as clean as Fox Business made it sound: CNBC has CVS's CEO saying the PBM and the stores will still work together under commercial agreements after they separate.

The receipts — 5 facts one side's coverage lacks
  • CEO David Joyner said synergy between the two businesses would be preserved in commercial agreements after the split official statementin CNBC · absent from right-leaning coverage
  • CVS, UnitedHealth, and Cigna together control roughly 80% of the market numberin Guardian · absent from right-leaning coverage
  • Joyner told the Wall Street Journal the company was not splitting because of regulatory issues official statementin CNBC · absent from right-leaning coverage
  • Existing investors will receive shares in both companies tax-free official statementin Fox Business · absent from left-leaning coverage
  • In its challenge to Tennessee's law, CVS argued it already reimburses nonaffiliated pharmacies at the same or higher rate than affiliated ones and is prohibited from steering patients to its own pharmacies official statementin Fox Business · absent from left-leaning coverage
The Left View
Left-leaning outlets framed the move as closing a chapter of healthcare conglomerates they say grew too dominant and costly. The Guardian tied it to lawmaker and regulator pressure, noting that CVS, UnitedHealth and Cigna control roughly 80% of the relevant market, quoting Arkansas Republican Jeremiah Moore on “crony capitalism,” and citing a Hawley–Warren antitrust bill that Senator Josh Hawley called “a major step toward restoring transparency and making health care more affordable for every American.” CNBC called the plan a “stunning reversal” of the vertical-integration bet and relayed analysts’ view that “relentless state legislative scrutiny” over combining a PBM with pharmacies may have mattered, even as Joyner said the decision came “out of strength” and was not driven by regulation—against the company’s earlier warning that a breakup would “open the door to private equity stripping the entire U.S. healthcare system for parts.”
The Right View
Right-leaning outlets described a healthcare “empire” coming apart in a way that Fox Business said “could slash prescription drug costs for millions and give independent pharmacies an edge.” Douglas Hoey of the National Community Pharmacists Association said it would be “good for competition, good for patients, lower prices, good for small businesses,” because CVS had been able to “decide how much their competition gets paid” and where patients fill prescriptions—what he called being “the judge, the jury and the executioner for all the other pharmacies.” Fox also flagged limits: specialty mail-order staying with the insurance and PBM side could leave steering and rebate conflicts intact for high-cost drugs, common shareholders would own both firms, and a standalone pharmacy might close more underperforming stores. The New York Post located the news in growing political and regulatory scrutiny of PBMs and of companies that combine insurance, drug-benefit management, and pharmacy operations.
Our Take (balanced)
The left’s strongest argument is that the split is best read against concentrated market power and a live antitrust campaign: three firms controlling roughly 80% of the market, new state bans on combined PBM-pharmacy ownership, a Hawley–Warren bill, and CVS’s own recent claim that a breakup would “open the door to private equity stripping the entire U.S. healthcare system for parts.” The right’s strongest argument, through the NCPA on Fox Business, is that common ownership let CVS both compete with other pharmacies and set their pay—Hoey’s “judge, the jury and the executioner” charge—and that ending that structure could be “good for competition, good for patients, lower prices,” with independents already down to about one-third of pharmacies. The central unresolved tension is whether two tickers and Joyner’s promised “commercial agreements” actually end that conflict—especially with Caremark, Aetna, and specialty pharmacy remaining together—or merely re-label a relationship regulators and independents still see as self-dealing.

8 sources

More stories

The week's bottom lines, in your inbox

One email a week: the five stories that mattered and what they actually mean. Free.